Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 13 2021

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Release

Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 13, 2021, titled "Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases